// App-Quantinova.ai

Filters

Biomarkers

No records found for your search

Conference Name

No records found for your search

Country

























Company

Search valid company name..

Conference Year













Drug











Disease

Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























45280 Abstracts

Assessing the ability of anti-C1q antibody measurement to predict a flare of lupus nephritis

Sameer Bahal - British Society for Rheumatology (BSR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Lupus nephritis

N/A

What do patients with lupus know about cardiovascular risk: could dietary modification be a promising therapeutic?

George A Robinson - British Society for Rheumatology (BSR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Sjogren's syndrome

N/A

Secukinumab provides sustained improvement of enthesitis in patients with ankylosing spondylitis: pooled analysis of four pivotal Phase 3 studies

Nick Barkham - British Society for Rheumatology (BSR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Ankylosing spondylitis

secukinumab

Assessing the differences in times to general practitioner presentation and diagnosis, and outcomes, for axial spondyloarthritis patients in different ethnic groups

Amanda Owusu-Agyei - British Society for Rheumatology (BSR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Peripheral spondyloarthritis

N/A

Real world efficacy of secukinumab: a single centre experience

Tim Blake - British Society for Rheumatology (BSR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Ankylosing spondylitis

secukinumab

The Multidimensional Health Assessment Questionnaire (MDHAQ) and the Heath Assessment Questionnaire Disability Index (HAQDI): a comparison in patients with psoriatic arthritis

Weiyu Ye - British Society for Rheumatology (BSR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Dermatology

Psoriatic arthritis

N/A

Delaying diagnosis: inflammatory back pain and the other features of suspected spondyloarthritis have been rarely featured in musculoskeletal health professions literature

Carol McCrum - British Society for Rheumatology (BSR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Spondyloarthritis

N/A

Biologic retention in psoriatic arthritis: a real world study

Issrah Jawad - British Society for Rheumatology (BSR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Dermatology

Psoriatic arthritis

N/A

Taking eosinophilia more seriously

Zoe Rutter-Locher - British Society for Rheumatology (BSR) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

What’s the chance of precipitation?

Ruth Smith - British Society for Rheumatology (BSR) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Systematic review of COPD re-exacerbation and exacerbation treatment failure definitions used in randomised controlled trials (RCTs)

Wilhelmine Meeraus - European Respiratory Society (ERS) , 2018

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Chronic obstructive pulmonary disease

N/A

Reframing asthma and inhaled corticosteroids (ICS) to modify treatment beliefs: an online randomised controlled trial

Caroline B. Katzer - European Respiratory Society (ERS) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Asthma

T-150

Investigation of relationships between inflammation and brain disease in COPD

Mohani-Preet Kaur Bajaj - European Respiratory Society (ERS) , 2018

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Coronary Artery Disease

Fibrinogen (IV)

Early experience of oxygen enhanced magnetic resonance imaging (OE-MRI) in ataxia telangiectasia (A-T)

Andrew Prayle - European Respiratory Society (ERS) , 2018

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Ataxia telangiectasia

N/A

An exploratory questionnaire to assess the confidence levels of practice nurses when managing asthma in children within local General Practices

Anita Critchlow - European Respiratory Society (ERS) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Asthma

N/A

emPHasis-10 score predicts mortality in patients with pulmonary hypertension

Stephen John Wort - European Respiratory Society (ERS) , 2018

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Congenital heart disease

N/A

Open-label extension (OLE) of ORBIT-3 and ORBIT-4 trials of ARD-3150 in non-cystic fibrosis bronchiectasis (NCFB)

Anne O'Donnell - European Respiratory Society (ERS) , 2018

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Cystic Fibrosis

ARD-3150

The association of vigorous physical activity with 10-year adult asthma incidence

Melissa Russell - European Respiratory Society (ERS) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Asthma

N/A

Physical activity enhancing programme (PAEP) in COPD – a randomised controlled trial

Leandro Mantoani - European Respiratory Society (ERS) , 2018

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Depression

N/A

Review of acute NIV outcomes over four years in a university hospital

Joanna Lovett - European Respiratory Society (ERS) , 2018

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Copyright © 2026. QuantiNova All rights reserved